Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
VTR
$78.71+Infinity%1D
Analyst Views on VTR
Wall Street analysts forecast VTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTR is 82.00 USD with a low forecast of 73.00 USD and a high forecast of 91.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast VTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTR is 82.00 USD with a low forecast of 73.00 USD and a high forecast of 91.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 77.860
Low
73.00
Averages
82.00
High
91.00
Current: 77.860
Low
73.00
Averages
82.00
High
91.00
KeyBanc
Austin Wurschmidt
Overweight
maintain
$70 -> $85
2025-12-04
Reason
KeyBanc
Austin Wurschmidt
Price Target
$70 -> $85
2025-12-04
maintain
Overweight
Reason
KeyBanc analyst Austin Wurschmidt raised the firm's price target on Ventas to $85 from $70 and keeps an Overweight rating on the shares. The firm continues to favor Healthcare REITs with exposure to above-average growth in senior housing operating fundamentals, and investment pipelines that support accretive external growth. While KeyBanc is incrementally constructive on companies with growing Senior Housing Operating Portfolio exposure, earnings accretion, available dry powder and operating execution may be key to gain investor confidence. The firm also expects skilled nursing fundamentals to remain attractive in 2026 but continues to monitor the reimbursement backdrop following the elimination of enhanced FMAP funding, but view rent coverage levels to be relatively healthy.
Wells Fargo
Overweight
maintain
$80 -> $88
2025-11-25
Reason
Wells Fargo
Price Target
$80 -> $88
2025-11-25
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Ventas to $88 from $80 and keeps an Overweight rating on the shares. The firm says that despite a few high-profile exceptions, most REITs delivered Q3 2025 earnings and outlooks reflecting healthy operating conditions despite macro and labor market concerns.
BofA
Jeffrey Spector
Buy
upgrade
$84 -> $91
2025-11-17
Reason
BofA
Jeffrey Spector
Price Target
$84 -> $91
2025-11-17
upgrade
Buy
Reason
BofA analyst Jeffrey Spector raised the firm's price target on Ventas to $91 from $84 and keeps a Buy rating on the shares. While stock performance did not reflect it, Q3 earnings season was "strong" for U.S. REITs as 69% of REITs beat the Street, the analyst tells investors in a note on the group.
Scotiabank
Nicholas Yulico
Sector Perform
maintain
$74 -> $80
2025-11-13
Reason
Scotiabank
Nicholas Yulico
Price Target
$74 -> $80
2025-11-13
maintain
Sector Perform
Reason
Scotiabank analyst Nicholas Yulico raised the firm's price target on Ventas to $80 from $74 and keeps a Sector Perform rating on the shares. The firm is updating its price targets for U.S. Real Estate & REITs stocks under its coverage, the analyst tells investors.
About VTR
Ventas, Inc. is a real estate investment trust (REIT). The Company holds a portfolio that includes senior housing communities, outpatient medical buildings, research centers, hospitals and healthcare facilities located in North America and the United Kingdom. The Company owns approximately 1,400 properties in North America and the United Kingdom. It operates in three segments: senior housing operating portfolio (SHOP), outpatient medical and research portfolio (OM&R), and triple-net leased properties (NNN). In its SHOP segment, it owns and invests in senior housing communities. It engages third-party managers to operate the communities on its behalf. In its OM&R segment, it primarily acquires, owns, develops, leases and manages outpatient medical buildings and research centers. In its NNN segment, it invests in and owns senior housing communities, skilled nursing facilities (SNFs), long-term acute care facilities (LTACs), and freestanding inpatient rehabilitation facilities (IRFs).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
